-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Office of the Procurement Working Group of Guangxi Autonomous Region Pharmaceutical Group issued a notice that, in order to further reduce the transaction costs of drugs, 100 commonly used drugs will be collected.
According to the list of purchased varieties published by Guangxi, it can be found that 86 of the 100 varieties are injections, including Oxiracetam, cerebrosine carnosine, Ida Lafeng, Prostial, vancomycin, yew alcohol lipids, calcium peroheparin, adenosine methionine and many other clinical varieties, there are many national and provincial key monitoring catalog products.
it is known that injections are the main clinical dosage forms in China.
, injections account for more than 60% of China's public hospital drug market, with chemical injections as high as 70%.
addition, there are data show that in 2018 the market size of injections has exceeded trillion yuan, including some annual sales of hundreds of millions, or even billions of large varieties.
Guangxi will carry out the collection of injectable drugs there is no shortage of large varieties, the industry believes that, as a pilot province of drug collection, this time there are 86 injections into the Guangxi GPO belt procurement, or means that the local version of the injection belt procurement will be gradually implemented.
In fact, with Guangxi for the common injection large varieties of large varieties to carry out a volume procurement pilot, to inject large varieties of procurement amount, large amount of characteristics, the industry predicts that the next injection will become the target of belt procurement around will be further accelerated, trillion market shuffle is coming.
, in addition to Guangxi, in fact, there have been Shandong, Shaanxi, Fujian, Qinghai and other provinces and cities have started the injection volume procurement.
For example, in April this year, Shanxi pharmaceutical centralized bidding procurement network issued a notice, announced the opening of the province's first batch of drug group alliance centralized volume procurement pilot, involving varieties are common injectable large varieties, involving breathing, blood, tumors, anesthesia, nerves and other drug use areas.
Health Insurance Bureau of Shandong Province also issued a notice in April, saying that it had identified 40 centralized drug varieties in accordance with the principles of large clinical use, high procurement amount and sufficient competition.
of which involves the best-selling anti-blood pressure drugs, proton pump inhibitors, contrast agents, anesthetics, anti-tumor drugs, anti-thrombosis drugs and so on.
in terms of dosage form, 28 of the 40 varieties were injections.
people in the industry generally believe that, with the continuous development of provincial collection will accumulate experience for the national collection, a new round of national collection will soon begin.
In July this year, the State Health Insurance Administration issued a catalogue of 500 varieties of striped procurement to provinces and municipalities, with the selection criteria for sorting by the purchase amount, covering about 500 of the top 80 percent of medicines, with plans to cover 250 by 2021 and 2022.
, it is worth noting that the National Health Insurance Administration is expected to carry out two batches per year as the collection becomes normal.
At present, the drug regulatory department has accelerated the progress of consistent evaluation of injectable generic drugs, more than two enterprises at the same time waiting for the evaluation of varieties has reached about 150, from next year, will gradually increase the proportion of injectable varieties in the national collection.
to this, industry insiders pointed out that the relevant pharmaceutical companies should be prepared to reduce prices, in the provincial market, with the policy of rational price reduction, do not leave excess "water."
addition, in the context of cracking down on commercial bribery, pharmaceutical companies and sales staff should also adhere to good compliance and legal, do not have problems.